Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Antibodies

Pemetrexed

Immunomodulating Agents

Immunoglobulins

Tubulin Modulators

Antimitotic Agents

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.

Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.

Carrelizumab

Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.

Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)

Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.

Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)

Surgery

Yongde Liao, PhD

Mingliang Wang, MD

The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in combination with platinum doublet neoadjuvant chemotherapy before surgery \[neoadjuvant phase\], followed by Camrelizumab alone after surgery \[adjuvant phase\] in participants with unresectable stage III non-small cell lung cancer.

Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with unresectable stage III non-small cell lung cancer(NSCLC), although surgery offers the chance of cure. With combined radiation and chemotherapy, the prognosis of unresectable stage III NSCLC remains poor. Immunotherapy combined with chemotherapy has been shown to be efficacious as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without targetable genetic aberrations. Camrelizumab, a humanised monoclonal antibody against PD-1, has shown its efficacy in the treatment of advanced NSCLC. This study is to studying neoadjuvant camrelizumab plus double platinum based chemotherapy followed by surgery to see how well it works in treating patients with unresectable stage III NSCLC.

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Induction Therapy With Chemoimmunotherapy Followed by Surgery for Unresectable Stage III Non-small Cell Lung Cancer: a Single-center, Single-arm, Prospective Clinical Study

MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy.

Resectability rate is defined as the percentage of patients who were able to undergo surgery after neoadjuvant therapy.

The incidences and types of adverse events that occur during neoadjuvant therapy and perioperative period (within postoperative 30 days and 90 days) will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Wuhan Union Hospital, China

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Pembrolizumab

Trastuzumab

Pertuzumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer

Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer

Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer

Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle

Eribulin

Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle

Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle

pertuzumab

Pyrotinib

Pembrolizumab，200mg，Intravenous infusion，3-week cycle

Camerlizumab，200mg，Intravenous infusion，3-week cycle

Camerlizumab

Jianli Dr. Zhao, doctor

Ying Dr. Wang, doctor

Ying Wang

Jianli Zhao

Chemotherapy is an important means to prolong the survival time of advanced breast cancer. As a new type of microtubule inhibitor, eribulin has a unique mechanism of action. Compared with single drug chemotherapy, it can improve the overall survival time of 2.5 months, increase the clinical benefit rate by 5 times, and the tolerance of eribulin is good. Therefore, the guidelines at home and abroad recommend eribulin for the rescue of advanced breast cancer.

However, up to now, there is no large sample data on the efficacy of eribulin combined with anti HER2 targeted therapy in HER2 + metastatic breast cancer, and the efficacy of combined immunotherapy in triple negative metastatic breast cancer. Moreover, as a newly marketed chemotherapy drug in China, the efficacy and safety data of eribulin in Chinese population are relatively lacking. Therefore, we plan to include different types and line numbers of advanced breast cancer patients based on the Chinese population through real-world research, and receive the treatment regimen containing eribulin respectively. In HR + / her2-mbc, we use eribulin monotherapy; in HER2 + MBC, we use eribulin + anti HER2 targeted therapy; in TNBC, we use eribulin + immunotherapy / chemotherapy, The efficacy and safety of eribulin were evaluated.

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

A Real-world Study: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

the diameter of target lesions diminished more than 30% and lasted for 4 weeks

the sum of the maximum diameter of the target lesion is smaller than PR, or the increase is not up to PD

he sum of the maximum diameter of the target lesion increased by at least 20%, and its absolute value increased by at least 5 mm, New lesions are also considered as PD

according to recist1.1 criteria, the proportion of patients whose best remission is CR or PR in the total number of evaluable patients.

according to recist1.1 criteria, the proportion of patients with Cr or PR or SD ≥ 24 weeks in the total number of evaluable patients.

Objective to explore the correlation between biomarkers and the ORR. The biomarkers will be test by nest-generation sequence, which include 520 genes and tumor mutation burden, like ERBB2/TP53/PIK3CA/ERBB4/CCND1 and so on.

The probability and severity of adverse reactions were analyzed up to 2 year after enrollment

The time from the beginning of treatment to the progression or death of the patient

The time from the beginning of treatment to the death of the patient

The quality of life score of patients during treatment was analyzed（FACT-B）. Performance Status Rating (PSR) was demonstrated for the FACT-B total score, which is the result of the following subscale scores: SWB (the Social / family Well-Being subscale) , EWB (the Emotional Well-Being subscale), AC (Additional Concerns subscale), PWB (the Physical Well-Being subscale), FWB (the Functional Well-Being subscale) Performance Status Rating (PSR) was demonstrated for the FACT-B total score, which is the result of the following subscale scores: SWB (the Social / family Well-Being subscale) , EWB (the Emotional Well-Being subscale), AC (Additional Concerns subscale), PWB (the Physical Well-Being subscale), FWB (the Functional Well-Being subscale)

all target lesions disappeared, no new lesions appeared, and tumor markers were normal, which lasted for at least 4 weeks

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC	NCT04943029	Non Small Cell ...	Carrelizumab Pemetrexed (Non... Carboplatin Surgery	18 Years - 70 Years	Wuhan Union Hospital, China
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC	NCT04943029	Non Small Cell ...	Carrelizumab Pemetrexed (Non... Carboplatin Surgery	18 Years - 70 Years	Wuhan Union Hospital, China
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer	NCT04683445	Breast Cancer	Eribulin Trastuzumab pertuzumab Pyrotinib Pembrolizumab Camerlizumab	18 Years - 80 Years	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC	NCT04943029	Non Small Cell ...	Carrelizumab Pemetrexed (Non... Carboplatin Surgery	18 Years - 70 Years	Wuhan Union Hospital, China

Spots Global Cancer Trial Database for camerlizumab

Every month we try and update this database with for camerlizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.